NCT05591352

Brief Summary

To assess Chenopodium formosanum extracts on skin condition improvement

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 19, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 24, 2022

Completed
8 days until next milestone

Study Start

First participant enrolled

November 1, 2022

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 13, 2023

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2023

Completed
Last Updated

November 9, 2023

Status Verified

November 1, 2023

Enrollment Period

2 months

First QC Date

October 19, 2022

Last Update Submit

November 7, 2023

Conditions

Outcome Measures

Primary Outcomes (4)

  • The change of skin wrinkles

    VISIA Complexion Analysis System was utilized to measure skin wrinkles. Units: arbitrary units

    Change from Baseline skin wrinkles at 8 weeks

  • The change of skin texture

    VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units

    Change from Baseline skin texture at 8 weeks

  • The change of skin collagen density

    DermaLab® Series SkinLab Combo was utilized to measure skin pores. Units: arbitrary units

    Change from Baseline skin collagen density at 8 weeks

  • The change of skin elasticity

    Cutometer® MPA580 was utilized to measure skin elasticity. Units: arbitrary units

    Change from Baseline skin elasticity at 8 weeks

Secondary Outcomes (7)

  • The change of skin melanin index

    Change from Baseline skin melanin index at 8 weeks

  • The change of skin L* value

    Change from Baseline L* value at 8 weeks

  • The change of skin erythema index

    Change from Baseline skin erythema index at 8 weeks

  • The change of skin moisture

    Change from Baseline skin moisture at 8 weeks

  • The change of transepidermal water loss (TEWL)

    Change from Baseline TEWL at 8 weeks

  • +2 more secondary outcomes

Other Outcomes (3)

  • The change of liver function biomarkers (AST, ALT) of blood

    Change from Baseline liver function biomarkers at 8 weeks

  • The change of renal function biomarkers (creatinine, BUN) of blood

    Change from Baseline renal function biomarkers at 8 weeks

  • The change of self-assessment skin condition

    Change from Baseline skin condition at 8 weeks

Study Arms (2)

Placebo sachet

PLACEBO COMPARATOR

consume 1 sachet per day

Dietary Supplement: Placebo sachet

Chenopodium formosanum extracts sachet

EXPERIMENTAL

consume 1 sachet per day

Dietary Supplement: Chenopodium formosanum extracts sachet

Interventions

consume 1 sachet per day

Also known as: Formosa Ruby sachet
Chenopodium formosanum extracts sachet
Placebo sachetDIETARY_SUPPLEMENT

consume 1 sachet per day

Placebo sachet

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy adults aged above 20 years old

You may not qualify if:

  • Subject who is not willing to participate in this study.
  • Patients with diseases of the skin, liver, kidney.
  • Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder.
  • Female who is pregnant or nursing or planning to become pregnant during the course of the study.
  • Received facial laser therapy, chemical peeling or UV overexposure (\> 3 hr/week) in the past 4 weeks.
  • Constant drug use
  • Students who are currently taking courses taught by the principal investigator of this trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chia Nan University of Pharmacy & Science

Tainan, 71710, Taiwan

Location

MeSH Terms

Conditions

Skin Diseases

Condition Hierarchy (Ancestors)

Skin and Connective Tissue Diseases

Study Officials

  • Chia-Hua Liang

    Chia Nan University of Pharmacy & Science

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 19, 2022

First Posted

October 24, 2022

Study Start

November 1, 2022

Primary Completion

January 13, 2023

Study Completion

September 30, 2023

Last Updated

November 9, 2023

Record last verified: 2023-11

Locations